目的 初步探討生長激素釋放激素受體（GHRHR）在腎上腺腫瘤組織中的表達及其在臨床中的實際應用價值。 方法 應用免疫組織化學方法檢測2001年1月－2009年10月間187例腎上腺腫瘤和20例正常腎上腺組織標本中GHRHR的表達。 結果 腎上腺皮質腫瘤與腎上腺髓質腫瘤、正常腎上腺組織比較，GHRHR表達明顯增高（陽性率分別為99%、45%、55%），GHRHR在腎上腺皮質醇瘤和醛固酮瘤中表達的差異有統計學意義，在腎上腺皮質腺瘤、皮質腺癌、皮質增生中表達的差異有統計學意義。 結論 GHRHR在人正常腎上腺及腎上腺腫瘤組織中的表達，為在垂體外組織及人類腫瘤組織存在GHRHR的表達提供了直接證據；GHRHR可能會用于腎上腺皮質腫瘤和髓質腫瘤的鑒別診斷，但GHRHR尚不能用于良性和惡性腎上腺皮質腫瘤的鑒別診斷。GHRHR在腎上腺皮質相關腫瘤的高表達，可能與腎上腺皮質腫瘤的發病機制有關。
目的 研究尿標本中防腐劑鹽酸對24 h尿游離皮質醇測定的影響。 方法 收集2008年7月-2009年1月正常人、庫欣病患者及其他疾病患者的24 h尿液，混勻后，一部分濃鹽酸防腐，一部分未加鹽酸直接保存。電化學發光免疫分析法同步檢測尿游離皮質醇濃度。 結果 經配對 t 檢驗加濃鹽酸后的24 h尿游離皮質醇測值均高于未加酸者，比較有統計學意義（Plt;0.05）。加鹽酸和未加鹽酸所測尿游離皮質醇二者之間具有較好的相關性，相關系數 r =0.97，P lt;0.05。 結論 濃鹽酸防腐的標本24 h尿游離皮質醇測值較未加酸保存的標本高。因此，為了得到相對準確的值，更好地反映腎上腺實際分泌情況，測定24 h尿游離皮質醇的標本不應使用鹽酸防腐。
目的:評價免疫印跡法檢測胰島自身抗體（GAD-A、ICA、IAA）與酶聯免疫法測ICA、GAD-A放射免疫法測IAA結果的一致性。方法:采用免疫印跡法測定81例糖尿病患者胰島自身抗體,將結果與酶聯免疫法測定的GAD-A、ICA,放射免疫法測定IAA結果進行比較。結果:免疫印跡法陽性檢出率為:GAD-A 51.8%,ICA 18.5%,IAA 27.1%；酶聯免疫法（GAD-A、ICA）、放射免疫法（IAA）陽性檢出率:GAD-A 32.1%,ICA 34.5%,IAA 30.8%；上述兩組結果進行比較,兩組相比ICA和GAD-A有統計學差異（Plt;0.05）,IAA無統計學差異。兩組結果一致率比較:GAD-A 50.6%,ICA 64.2%,IAA 69.1%。結論:與臨床常用酶聯免疫法檢測GAD-A、ICA,放射免疫法檢測IAA比較,免疫印跡法和酶聯免疫法在ICA及GAD-A陽性檢出率上的差異有顯著性,和放射免疫法在IAA陽性檢出率上差異無顯著性。
Objective To evaluate the safety and efficacy of venlafaxine and carbamazepine on painful peripheral diabetic neuropathy. Methods This was a randomized, parallel-group, double-blind, double-dummy clinical trial. 132 patients a venlafaxine group (n=66) and a carbamazepine group (n=66) with painful peripheral diabetic neuropathy were recruited from 3 clinical centers. The venlafaxine group took venlafaxine 25 mg plus one dummy carbamazepine tablet twice a day and the carbamazepine group took carbamazepine 0.1 g plus one dummy venlafaxine tablet twice a day both for 2 weeks. The primary efficacy measurement consisted of a numeric pain intensity scale and the secondary measurement assessed quality of life. Results One hundred and nineteen patients completed the trial. Venlafaxine was superior to carbamazepine in improving mean pain intensity scores at 5,7,10 and 14 days by per-protocol analysis (P=0.02, P=0.03, P=0.003 and P=0.001 respectively). The effects of venlafaxine on the improvement in the total quality of life scores were better than those of carbamazepine at 10 and 14 days (P=0.02 and P=0.01 respectively). Sleep interference and mood were improved by both venlafaxine and carbamazepine, but the efficacy of venlafaxine was superior to that of carbamazepine. The common adverse events of venlafaxine included mild gastrointestinal discomfort, dizziness and somnolence. The frequency of adverse events in the venlafaxine group was about 43.9% (4 patients withdrew because of adverse events) and in the carbamazepine group about 25.76% (2 patients withdrew because of adverse events) (P =0.06). Conclusions Venlafaxine and carbamazepine are effective in the treatment of painful diabetic neuropathy, venlafaxine is superior to carbamazepine in improving pain and quality of life. Both drugs may be safe and well tolerated.